跳至主要内容
临床试验/NCT01980836
NCT01980836Unknown4 期

The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis

Tel-Aviv Sourasky Medical Center2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
4 期
入组人数
40
试验地点
2
主要终点
Cellular response

研究概览

简要总结

Patients with rheumatoid arthritis (RA) are prone to respiratory infections and therefore recommmended to receive vaccination against seasonal influenza. We and others have shown a relatively preserved humoral response to vaccination in RA patients. However, the cellular response as well as the effect of biologics such as tocilizumab on the cellular response has not been weel studied. The purpose of this study is the evaluate the effect of tocilizumab on the cellular immune response to influenza vaccine in patients with RA in comparison with healthy controls

详细描述

Inclusion criteria :

  • RA patients
  • Above the age of 18
  • Treated with tocilizumab at least 3 months

Exclusion criteria:

-egg allergy

Design of the study :

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Rheumatoid Arthritis patients treated with Tocilizumab for at least 3 months
  • Above the age of 18

排除标准

  • Allergy to eggs

结局指标

主要结局

Cellular response

时间窗: 4 weeks

As described in the study design using the Interferin gamma and granzyme B levels

次要结局

  • Humoral response(4 weeks)

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验